Gut microbiota metabolite 4-OH-PLA reduces allergy risks
Nearly one in three children in France lives with at least one allergic condition, and asthma remains the most frequent chronic pathology affecting between 7 to 10 percent of children, according to figures from Inserm cited by futura-sciences.com. Eczéma, allergic rhinitis, food allergies, and asthma attacks now appear earlier in life, sometimes during the very first years. An international study published in Nature Microbiology points to a protective mechanism originating in the infant gut microbiota during the initial months after birth.
Key Clinical Takeaways:
- Gut bacteria produce a specific metabolite called 4-hydroxyphenyl lactate (4-OH-PLA) that acts as a brake on allergic reactions.
- Laboratory tests on human immune cells show that 4-OH-PLA reduces immunoglobulin E (IgE) production by about 60 percent.
- Factors such as vaginal birth, exclusive breastfeeding, and early social interaction significantly increase the acquisition of these protective bifidobacteria.
Microbial Metabolites Calming the Immune System
These bacteria produce metabolites capable of modulating immune responses. Farm children present up to 80 percent lower risks of developing asthma or eczema compared to urban children, highlighting a long-standing epidemiological paradox connecting animal exposure, hygiene theory, and the microbiome.
Among the metabolites identified, 4-hydroxyphenyl lactate (4-OH-PLA) acts as a brake on allergic reactions. In experiments on human immune cells, this compound strongly reduced the production of immunoglobulin E (IgE), the key antibody involved in hay fever, eczema, and asthma.
The main advancement is the identification of a precise mechanism capable of inhibiting the development of allergic responses in early childhood,
noted Susanne Brix Pedersen, professor at DTU Bioengineering and project leader, as reported by futura-sciences.com.
At concentrations naturally observed in the infant gut, 4-OH-PLA decreases IgE production by approximately 60 percent without disrupting other antibodies necessary for general immunity. The body’s overall defense remains intact while allergic hyperreactivity is contained.
Longitudinal Findings Across Five Years of Childhood
To confirm this biological link, researchers tracked 147 children from birth to the age of five, analyzing their gut microbiota composition, produced metabolites, and the evolution of immune markers. Infants with a high presence of specific bifidobacteria during their first months of life showed significantly lower susceptibility to subsequent allergic sensitizations.
Genetic stool analyses mapped the bacteria involved and the substances they produced, establishing a biological connection between the microbiome and immune system maturation. Natural factors favoring this beneficial colonization include vaginal birth, exclusive breastfeeding, and early interactions with other children.
Children born vaginally are up to fourteen times more likely to acquire these bifidobacteria from their mother,
explained Rasmus Kaae Dehli, immunologist at DTU, according to futura-sciences.com.
Clinical Trials Underway in Denmark
Because these bacteria grow scarcer in modern Western societies, researchers suggest that targeted supplementation could compensate for the loss. Introducing bifidobacteria capable of producing 4-OH-PLA or their direct metabolites could pave the way for new probiotic supplements or enriched infant formulas intended for at-risk infants.
Clinical trials are currently underway in Denmark through the Begin study, aiming at the early prevention of asthma and allergies. If these results are confirmed, targeted preventive strategies could emerge in the coming years.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.